JPMorgan Encouraes Investors to Buy Onyx Pharm. (ONXX) on Dip, Notes CFZ Approval is a Given
Tweet
Share
E-mailGet Alerts ONXX Hot Sheet
Price: $124.70 --0%
Rating Summary:
9 Buy, 12 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
9 Buy, 12 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Analysts at JPMorgan are encouraging investors to buy shares of Onyx Pharmaceuticals Inc. (Nasdaq: ONXX) while they’re trading down 5.2 percent on the day.
An analyst at the firm notes the CFZ approval is now more of a question when and not what if.
JPMorgan is reaffirming its Overweight rating and $48 price target on shares of ONXX.
An analyst at the firm notes the CFZ approval is now more of a question when and not what if.
JPMorgan is reaffirming its Overweight rating and $48 price target on shares of ONXX.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
- Cummins (CMI) PT Lowered to $675 at Jefferies
- Ferrovial SA (FER:SM) (FRRVF) Reiterated at Buy by UBS on Winning Bid For Tennessee Project
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
